{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:01:40Z","timestamp":1783033300264,"version":"3.54.6"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","heartandlung.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.hrtlng.2025.10.001","type":"journal-article","created":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T15:58:28Z","timestamp":1760198308000},"page":"198-204","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Repurposing sodium glucose cotransporter-2 (SGLT-2) inhibitors in sarcoidosis: A potential strategy for reducing mortality"],"prefix":"10.1016","volume":"75","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-2209-8255","authenticated-orcid":false,"given":"A B M Nasibul","family":"Alam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natasha","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reina","family":"Nagasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laeeq","family":"Shamsuddin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.hrtlng.2025.10.001_bib0001","doi-asserted-by":"crossref","first-page":"499","DOI":"10.5694\/mja17.00610","article-title":"Sarcoidosis: a state of the art review from the thoracic society of Australia and New Zealand","volume":"208","author":"Ahmadzai","year":"2018","journal-title":"Med J Aust"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.10.001_bib0002","first-page":"19","article-title":"Sarcoidosis: evaluation and Treatment","volume":"109","author":"Partin","year":"2024","journal-title":"Am Fam Physician"},{"issue":"12","key":"10.1016\/j.hrtlng.2025.10.001_bib0003","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.2174\/1389557521666211013112211","article-title":"A rapid qualitative review of sarcoidosis: clinical manifestations, immunopathogenesis, diagnosis and treatment","volume":"22","author":"Shahgaldi","year":"2022","journal-title":"Mini Rev Med Chem"},{"key":"10.1016\/j.hrtlng.2025.10.001_bib0004","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2024.103179","article-title":"Developmental drugs for sarcoidosis","volume":"149","author":"Obi","year":"2024","journal-title":"J Autoimmun"},{"key":"10.1016\/j.hrtlng.2025.10.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaut.2023.103107","article-title":"Pulmonary sarcoidosis: a comprehensive review: past to present","volume":"149","author":"Belperio","year":"2024","journal-title":"J Autoimmun"},{"issue":"4","key":"10.1016\/j.hrtlng.2025.10.001_bib0006","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1164\/rccm.202402-0265OC","article-title":"The Renin-Angiotensin-Aldosterone System Regulates Sarcoidosis Granulomatous Inflammation","volume":"210","author":"Crouser","year":"2024","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.hrtlng.2025.10.001_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.950095","article-title":"Re-evaluating serum angiotensin-converting enzyme in sarcoidosis","volume":"14","author":"Zheng","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.hrtlng.2025.10.001_bib0008","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1146\/annurev-med-051013-110046","article-title":"The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus","volume":"66","author":"Vallon","year":"2015","journal-title":"Annu Rev Med"},{"issue":"11","key":"10.1016\/j.hrtlng.2025.10.001_bib0009","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.2337\/dci22-0034","article-title":"Management of Hyperglycemia in Type 2 Diabetes, 2022. A consensus report by the American diabetes association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"45","author":"Davies","year":"2022","journal-title":"Diabetes Care"},{"issue":"5","key":"10.1016\/j.hrtlng.2025.10.001_bib0010","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1016\/j.kint.2022.08.012","article-title":"Diabetes management in chronic kidney disease: a consensus report by the American Diabetes Association (ADA) and kidney disease: improving Global Outcomes (KDIGO)","volume":"102","author":"de Boer","year":"2022","journal-title":"Kidney Int"},{"issue":"18","key":"10.1016\/j.hrtlng.2025.10.001_bib0011","first-page":"e895","article-title":"2022 AHA\/ACC\/HFSA Guideline for the Management of heart failure: a report of the american college of cardiology\/american heart association joint committee on clinical practice guidelines","volume":"145","author":"Heidenreich","year":"2022","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2025.10.001_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellsig.2024.111335","article-title":"Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits","volume":"122","author":"Forouzanmehr","year":"2024","journal-title":"Cell Signal"},{"issue":"3","key":"10.1016\/j.hrtlng.2025.10.001_bib0013","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.chest.2024.09.009","article-title":"Mortality and health outcomes among patients with sarcoidosis treated with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers","volume":"167","author":"Fares","year":"2025","journal-title":"Chest"},{"key":"10.1016\/j.hrtlng.2025.10.001_bib0014","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2021.738848","article-title":"Effects of SGLT2 Inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system","volume":"12","author":"Puglisi","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.10.001_bib0015","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-022-24280-9","article-title":"Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone and renin levels in diabetes mellitus type 2 patients: a systematic review and meta-analysis","volume":"12","author":"Manosroi","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.hrtlng.2025.10.001_bib0016","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20030629","article-title":"Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system","volume":"20","author":"Ansary","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.hrtlng.2025.10.001_bib0017","doi-asserted-by":"crossref","DOI":"10.3390\/ijms26041670","article-title":"Anti-Inflammatory effects of SGLT2 inhibitors: focus on macrophages","volume":"26","author":"Rykova","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"10","key":"10.1016\/j.hrtlng.2025.10.001_bib0018","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23105634","article-title":"Role of sodium-glucose co-transporter 2 inhibitors in the regulation of inflammatory processes in animal models","volume":"23","author":"Feijoo-Bandin","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.10.001_bib0019","doi-asserted-by":"crossref","DOI":"10.1016\/j.dsx.2023.102934","article-title":"Antifibrotic effects of sodium-glucose cotransporter-2 inhibitors: a comprehensive review","volume":"18","author":"Shakour","year":"2024","journal-title":"Diabetes Metab Syndr"},{"issue":"5","key":"10.1016\/j.hrtlng.2025.10.001_bib0020","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1097\/MCP.0000000000000893","article-title":"Novel insights in fibrotic pulmonary sarcoidosis","volume":"28","author":"Comes","year":"2022","journal-title":"Curr Opin Pulm Med"},{"issue":"7","key":"10.1016\/j.hrtlng.2025.10.001_bib21","doi-asserted-by":"crossref","DOI":"10.1042\/CS20171598","article-title":"Identification of protein phosphatase involvement in the AT2 receptor-induced activation of endothelial nitric oxide synthase","volume":"132","author":"Peluso","year":"2018","journal-title":"Clin Sci (Lond)"},{"key":"10.1016\/j.hrtlng.2025.10.001_bib22","doi-asserted-by":"crossref","first-page":"116062","DOI":"10.1016\/j.bcp.2024.116062","article-title":"Angiotensin AT2 receptors reduce inflammation and fibrosis in cardiovascular remodeling","volume":"222","author":"Kaschina","year":"2024","journal-title":"Biochem Pharmacol"},{"issue":"4","key":"10.1016\/j.hrtlng.2025.10.001_bib23","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/ijms26041670","article-title":"Anti-inflammatory effects of SGLT-2 inhibitors: Focus on Macrophages","volume":"26","author":"Rykova","year":"2025","journal-title":"Int J of Mol Sci"},{"issue":"5","key":"10.1016\/j.hrtlng.2025.10.001_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.tem.2024.02.003","article-title":"Systemic and organ-specific anti-inflammatory effects of Sodium Glucose Co-transporter-2 inhibitors","volume":"35","author":"Mashayekhi","year":"2024","journal-title":"Trends Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.10.001_bib25","doi-asserted-by":"crossref","first-page":"102934","DOI":"10.1016\/j.dsx.2023.102934","article-title":"Anti-fibrotic effects of Sodium-Glucose Co-Transporter-2 inhibitors: A comprehensive review","volume":"18","author":"Shakour","year":"2024","journal-title":"Diabetes Metab Syndr"},{"key":"10.1016\/j.hrtlng.2025.10.001_bib26","doi-asserted-by":"crossref","first-page":"103397","DOI":"10.1016\/j.jaut.2025.103397","article-title":"Advanced pulmonary sarcoidosis","volume":"152","author":"Jeny","year":"2025","journal-title":"J Autiimmun"},{"issue":"2","key":"10.1016\/j.hrtlng.2025.10.001_bib27","doi-asserted-by":"crossref","DOI":"10.1007\/s00418-010-0725-7","article-title":"Evidence of Na+-Glucose cotransporter in type 1 alveolar epithelium","volume":"134","author":"Bodega","year":"2010","journal-title":"Histochem Cell Biol"},{"issue":"1","key":"10.1016\/j.hrtlng.2025.10.001_bib28","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.116.232025","article-title":"Interaction of the Sodium\/Glucose Cotransporter (SGLT) 2 inhibitor Canagliflozin with SGLT1 and SGLT2","volume":"358","author":"Ohgaki","year":"2016","journal-title":"J Pharmacol Exp Ther"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956325002122?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956325002122?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:37:06Z","timestamp":1763566626000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956325002122"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":28,"alternative-id":["S0147956325002122"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2025.10.001","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Repurposing sodium glucose cotransporter-2 (SGLT-2) inhibitors in sarcoidosis: A potential strategy for reducing mortality","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2025.10.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}